Laennec
Human placenta hydrolysate — an injectable pooled human tissue extract
Laennec (Human placenta hydrolysate — an injectable pooled human tissue extract) is a longevity & bioregulators research compound. An enzymatic hydrolysate of pooled human placenta given by injection. Not a molecule and not a defined peptide: a digest of donated human tissue whose composition depends on the donors, the enzyme, the digestion time and the fractionation, none of which any vendor publishes. The proposal is that placental tissue is rich in growth factors, cytokines and nucleotides and that the hydrolysate delivers a regenerative mixture. No paper in this literature identifies an active constituent, assays it, or shows a dose-response.
Laennec quick facts
| Route | IM |
| Frequency | Not established · Not established |
| Half-life | No defined analyte, so no plasma curve and no half-life. The route argument is real; the numbers behind it do not exist |
| Forms | Injectable |
| Evidence level | Two rat papers from 1989 name Laennec itself. The human literature is about other manufacturers' placental extracts and contains no placebo-controlled trial. |
The most expensive item in this catalog, and its own named literature is two rat papers from one Japanese laboratory in 1989 — which contradict each other about whether intravenous or subcutaneous works better, and both of which report it did not prevent the pseudolobule formation that defines cirrhosis. The markers moved; the disease-defining feature did not. The only properly blinded randomized trial in this class compared one placental extract against another with no placebo arm, and found no change in estradiol or FSH — which rules out the hormonal explanation most buyers assume. It is pooled human tissue, injected, and none of the published sources describes donor screening or viral inactivation.
How Laennec works
An enzymatic hydrolysate of pooled human placenta given by injection. Not a molecule and not a defined peptide: a digest of donated human tissue whose composition depends on the donors, the enzyme, the digestion time and the fractionation, none of which any vendor publishes. The proposal is that placental tissue is rich in growth factors, cytokines and nucleotides and that the hydrolysate delivers a regenerative mixture. No paper in this literature identifies an active constituent, assays it, or shows a dose-response.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Laennec
Buy Laennec at RUPharma →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Laennec
Graded by what exists behind each claim.
✅ Clinically validated
- No placebo-controlled trial of this product exists, in any indication, in any country. The one properly blinded randomized trial in this class is a non-inferiority comparison of one placental extract against another with no placebo arm, scored on the Kupperman index, which by design cannot detect whether the class does anything (Kim 2023).
- That trial found no significant difference in estradiol or follicle-stimulating hormone — which rules out the hormonal explanation most buyers assume.
📊 Correlative data
- The only human study of a placental extract with a control group randomized 39 community-dwelling Koreans aged 65+, 22 to subcutaneous extract and 17 to saline, single-blind, with a self-reported questionnaire as the outcome. Between groups, only the physical function subscale reached significance (p=0.036) (Kong 2012).
- A 2025 editorial commentary describes human placental extract as promising in chronic liver disease (Liu 2025). An editorial is a considered opinion, not a dataset.
🧪 Theoretical / extrapolated
- An enzymatic hydrolysate of pooled human placenta given by injection — a digest of donated human tissue whose composition depends on the donors, the enzyme and the fractionation, none of which any vendor publishes. No paper identifies an active constituent or shows a dose-response.
- Its two named studies contradict each other about the route. The regeneration study concludes intravenous was much more potent than subcutaneous (Nakayama 1989a); the injury study concludes no therapeutic difference between them (Nakayama 1989b). Same laboratory, same year, and unresolved for thirty-seven years.
- Both report it did NOT inhibit pseudolobule formation. Pseudolobules are the architectural distortion that defines cirrhosis. The enzymes moved and the disease-defining feature did not.
- Predicted risk class, not a reported event: a pooled human tissue product given parenterally raises donor screening, viral inactivation and batch traceability questions, and none of the published sources describes any of them.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Laennec actually does
This is the most expensive item in the catalog it comes from, and its own named literature is two rat papers from 1989. A partner lists it at $557 — more than ten times most of the shelf and the only product on it no other partner carries. A PubTator3 search on 9 September 2026 returns two studies that name Laennec itself Nakayama 1989 Nakayama 1989, both from the same Japanese laboratory, both published in 1989, both in rats. Everything else in the human placenta extract literature is about a different manufacturer's product.
What the material actually is. An enzymatic hydrolysate of pooled human placenta given by injection. Not a molecule, not a defined peptide, not a recombinant protein — a digest of donated human tissue, whose composition depends on the donors, the enzyme, the digestion time and the fractionation, none of which any vendor publishes. That places it in the same evidentiary category as the organ extracts elsewhere in this catalog, with one difference that runs through the whole page: the tissue is human and the route is parenteral.
The mechanism on offer, and its honest status. The proposal is that placental tissue is rich in growth factors, cytokines and nucleotides, and that a hydrolysate delivers a mixture that promotes hepatocyte regeneration. Liu 2025 is a 2025 editorial commentary describing human placental extract as promising in chronic liver disease; an editorial is a considered opinion in a journal and it is not a dataset. No paper in this literature identifies an active constituent, assays it, or shows a dose-response for it.
And the strongest finding in the rat work is what it did not change. Both 1989 studies report improved transaminases and reduced vacuolation and necrosis, and both report that Laennec did not inhibit pseudolobule formation caused by carbon tetrachloride Nakayama 1989 Nakayama 1989. Pseudolobules are the architectural distortion that defines cirrhosis. The markers moved and the disease-defining feature did not, in the model, at the doses used, by the group developing the product.
Cell, rodent, human — and where it stops
The two named studies, in detail, because there are only two. Nakayama 1989 took normal rats and rats with CCl4-induced cirrhosis through roughly 70% partial hepatectomy and reports that intravenous or subcutaneous Laennec increased the regeneration rate of the residual liver, that intravenous dosing inhibited the fall in liver total protein and lowered serum GOT and GPT, and that it minimized vacuolation, necrosis and lipid deposition. Nakayama 1989 used acute carbon tetrachloride injury at 0.5 ml/kg for 4 days and chronic injury over 7 weeks, and reports both routes inhibiting the rise in GOT and GPT with intravenous dosing also inhibiting the alkaline phosphatase rise.
The two papers disagree with each other about the route, and that is worth seeing. The regeneration study concludes that the intravenous effect was much more potent than the subcutaneous one Nakayama 1989. The injury study concludes that no therapeutic difference was noted between intravenous and subcutaneous injection Nakayama 1989. Same laboratory, same year, same product, opposite conclusions on the one variable a buyer has to choose. Nobody has resolved it in the thirty-seven years since.
The human evidence is about a different product and it is small. Kong 2012 randomized 39 community-dwelling healthy Koreans aged 65 and over — 22 to abdominal subcutaneous human placental extract for 8 weeks and 17 to saline — in a single-blind design with a self-reported health-status questionnaire as the outcome. Within the treated group, physical function, sexual life and general health perception improved from baseline. Between the groups, only the physical function score differed (p = 0.036). Within-group change is not the test; the between-group comparison is, and one subscale out of several reached significance in 39 people who could see which injection they were getting.
The one properly blinded randomized trial compared a placental extract against another placental extract. Kim 2023 is a randomized, multicenter, double-blind, parallel non-inferiority study of Unicenta against Melsmon for menopausal symptoms, scored on the Kupperman index. Unicenta was non-inferior (p = 0.789 and p = 0.826), with no significant difference in estradiol or follicle-stimulating hormone, in facial flushing, or in adverse event rates (p = 0.505). Read precisely: two products of the same class performed alike, with no placebo arm. That establishes equivalence and says nothing about whether either works — and the absence of any hormone movement rules out the explanation most buyers assume.
Laennec pharmacokinetics — how much of it actually gets in
An undefined hydrolysate has no pharmacokinetics, and saying so precisely is more useful than pretending otherwise. There is no defined analyte, so there is no plasma curve, no half-life, no clearance route and no bioavailability figure for this product. None of the studies above reports a concentration of anything Nakayama 1989 Nakayama 1989 Kong 2012 Kim 2023. What can be reasoned about is the route, and the route is the one genuinely interesting pharmacokinetic question this product raises.
Why the route argument is real here and not on the oral shelf. A hydrolysate is by definition a mixture of peptides and amino acids already cut small by an enzyme. Swallowed, it would be digested to the same end point as any dietary protein, which is why no oral version of this product is sold. Injected, the mixture reaches circulation intact, and the two 1989 studies used intravenous and subcutaneous dosing for exactly that reason. This is one of the few products in this catalog where the parenteral route is not a marketing choice but the only route with a mechanism attached.
What the route difference should have told us, and did not. Subcutaneous absorption of a peptide mixture is slower, partly lymphatic, and lower in peak concentration than an intravenous bolus; intravenous delivers everything at once and clears faster. Two studies from one laboratory reported opposite conclusions about which worked better Nakayama 1989 Nakayama 1989, which is exactly the disagreement a single pharmacokinetic study would have settled. Nobody ran one.
The consequence for the human data. Kong 2012 used the subcutaneous route in older adults and Kim 2023 used injection for menopausal symptoms. Neither reports an exposure. So the human record and the animal record cannot be placed on the same axis even in principle, and the price of $557 buys a course whose delivered quantity of anything is unstated.
What would have to be true, and how you would know it was not
Three predictions. The first is the one the rat work implies and nobody has run in a person.
1. ALT, AST, GGT and alkaline phosphatase before and after a course. Both 1989 studies report falls in serum transaminases as their main biochemical result Nakayama 1989 Nakayama 1989, and these are among the cheapest and most standardized tests in medicine. Prediction in a healthy adult with normal baseline enzymes: no change, because there is no injury for the effect to reverse. That is the falsification, and it is also the reason the animal model's success does not transfer — the rats had chemically damaged livers.
2. Estradiol and follicle-stimulating hormone, for anybody taking it for a hormonal reason. The blinded trial measured both and found no significant change Kim 2023. Prediction: unchanged. Anyone told this product works hormonally should be shown that result first, because the one properly blinded study in the literature measured exactly that and reported nothing.
3. Against the product: grip strength and a timed walk at baseline and 8 weeks. The single positive human between-group finding was a self-reported physical function subscale in 39 single-blinded older adults Kong 2012. Objective versions of that construct exist, cost nothing, and cannot be moved by knowing which injection you received. Prediction: no difference. If it is wrong, that is the most interesting result anybody has produced for this product in thirty-seven years.
What nobody has tested yet
Nobody has run a placebo-controlled trial of this product. Not of Laennec specifically, in any indication, in any country, in the searchable literature. The blinded randomized trial that exists in this class is a non-inferiority comparison of one placental extract against another Kim 2023, which by design cannot detect whether the class does anything. That is the whole gap, and at $557 a course it is an expensive one.
Nobody has published a composition. No protein content, no peptide profile, no growth factor assay, no batch-to-batch consistency data, no potency standard. A hydrolysate of pooled human tissue is variable by construction, and without an assay there is no way to know whether two vials contain the same thing — which also means no way for a study to be replicated.
Nobody has published donor screening or viral inactivation details in the peer-reviewed record. This is a pooled human tissue product given by injection. The screening and inactivation steps are the most important safety facts about any such product, and none of the five sources on this page describes them. That is a question to put to a vendor in writing before buying, and the absence of a published answer is itself the finding.
Extrapolation, labeled as such. If the mechanism is delivery of regenerative signals to injured liver, three things follow that nobody has tested: the effect should be absent in an undamaged liver, which is measurable with a liver panel in healthy volunteers; it should scale with the degree of injury, which is measurable against baseline transaminases; and it should not change hormone concentrations, which is the one prediction that has been tested and held Kim 2023.
Laennec — its own safety story, not its class's
Three things this product owns, and the first is a category rather than a side effect.
It is pooled human tissue, injected. Nothing else in this catalog is. That changes the risk conversation from pharmacology to the questions asked of any human-derived biological: who were the donors, what were they screened for, what viral inactivation step was applied, and what is the batch traceability. None of the five sources on this page answers any of those Nakayama 1989 Nakayama 1989 Kong 2012 Kim 2023 Liu 2025. This is not a claim that the product is contaminated. It is the observation that the reassurance available is the manufacturer's word, and that a buyer should ask for the documentation rather than assume it.
Injecting a foreign protein mixture carries an allergic risk that a tablet does not. A hydrolysate of human tissue contains peptides an individual immune system has never met in that form and at that route. Hypersensitivity and injection-site reactions are the foreseeable events, and the one trial reporting comparative adverse events compared this class against itself rather than against placebo Kim 2023, so there is no placebo-controlled adverse event rate for the class at all.
And the liver claim invites the wrong self-diagnosis. The supporting animal work is in chemically injured livers Nakayama 1989 Nakayama 1989. Somebody with real liver disease needs a diagnosis and a hepatologist, not an unregulated injectable, and the specific harm this page is trying to prevent is somebody with rising transaminases treating them with this instead of finding out why they are rising. Nothing here is a diagnosis or a treatment recommendation.
Sources read for this page
- Nakayama S, Kodama K, Oguchi K. [A comparative study of human placenta hydrolysate (Laennec) by intravenous or subcutaneous injection on liver regeneration after partial hepatectomy in normal and CCl4-induced cirrhosis rats]. Nihon Yakurigaku Zasshi 1989 [Japanese] · PMID 2613108
- Nakayama S, Yamauchi M, Oguchi K. [A comparative study of Laennec by intravenous or subcutaneous injection on CCl4-induced acute or chronic liver injury in rats]. Nihon Yakurigaku Zasshi 1989 [Japanese] · PMID 2807070
- Kong M, Park SB. Effect of human placental extract on health status in elderly Koreans. Evidence-Based Complementary and Alternative Medicine 2012 · PMID 22454680
- Kim S, Lee S, Ahn KH, Park HT, Song JY, Hong SC, Kim T. A randomized, multicenter, double-blind, parallel, non-inferiority clinical study comparing Unicenta and Melsmon for menopausal symptom improvement. Medicina (Kaunas) 2023 · PMID 37629679
- Liu Y, Wang Y, Yang XJ. Revitalizing liver health: human placental extract shows promise in chronic liver disease management. World Journal of Clinical Cases 2025 [editorial commentary] · PMID 41113079
Laennec — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Laennec moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Laennec in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Laennec
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Laennec — frequently asked questions
What is Laennec?
Laennec (Human placenta hydrolysate — an injectable pooled human tissue extract) is a longevity & bioregulators research compound. An enzymatic hydrolysate of pooled human placenta given by injection. Not a molecule and not a defined peptide: a digest of donated human tissue whose composition depends on the donors, the enzyme, the digestion time and the fractionation, none of which any vendor publishes. The proposal is that placental tissue is rich in growth factors, cytokines and nucleotides and that the hydrolysate delivers a regenerative mixture. No paper in this literature identifies an active constituent, assays it, or shows a dose-response.
Where can I find Laennec dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Laennec protocol are available to members inside Skool. This public page covers what Laennec is, how it works and the evidence.
What is the half-life of Laennec?
Laennec has an approximate half-life of No defined analyte, so no plasma curve and no half-life. The route argument is real; the numbers behind it do not exist, which is part of what determines how often it's dosed.
What's the evidence behind Laennec?
Current evidence level: Two rat papers from 1989 name Laennec itself. The human literature is about other manufacturers' placental extracts and contains no placebo-controlled trial.. Laennec is offered for research purposes only and is not an approved medicine.
What Laennec is used for
Laennec appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.